Sensus Healthcare, Inc. (SRTS) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Sensus Healthcare, Inc. is a medical device company manufacturing radiation therapy devices (SRT-100 series) for oncological and non-oncological skin conditions. The company operates globally with a primary focus on the U.S. dermatology market. This report covers the quarterly period ended March 31, 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $8.34 million | $10.66 million |
| Gross Profit | $4.35 million | $6.66 million |
| Gross Margin | 52.2% | 62.5% |
| Operating Loss | $(2.65) million | $2.89 million (Income) |
| Net Loss | $(2.57) million | $2.27 million (Income) |
| Cash and Equivalents | $19.07 million | $14.73 million (End of Q1 2024) |
| Debt | $0 (No borrowings outstanding) | $0 |
| Working Capital | $47.47 million | $50.85 million (Dec 31, 2024) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 22.4% year-over-year, primarily driven by a lower volume of units sold to a single large U.S. customer who accounted for 69% of Q1 2025 revenue.
- Margin Compression: Gross margin fell from 62.6% to 52.2% due to lower sales volume and higher service costs.
- Expense Surge: Total operating expenses increased 85.4% to $7.0 million.
- R&D: Increased 188.9% to $2.61 million, driven by lobbying costs for billing code reimbursement and increased headcount.
- Selling & Marketing: Increased 69.2% to $2.19 million due to tradeshows, clinical studies, and payroll.
- G&A: Increased 37.5% to $2.21 million due to professional fees and compensation.
- Tax Rate: The effective tax rate turned negative (-4.5%) compared to 26.7% in the prior year, largely due to the utilization of estimated tax credits relative to pre-tax income.
Outlook, Risks, and Contingencies
- Liquidity: The company holds $19.1 million in cash and has a $15 million revolving credit facility with Comerica Bank (currently unutilized). Management believes resources are sufficient for the next 12 months.
- Customer Concentration: Significant risk exists due to reliance on one U.S. customer for 69% of revenue and 87% of accounts receivable.
- Legal Proceedings: The company is cooperating with a Department of Justice investigation regarding Medicare billing by a physician using Sensus devices. The company disputes any wrongdoing and has not estimated potential costs.
- Geopolitical & Economic Risks: Management monitors inflationary pressures on commodity and labor costs, as well as geopolitical uncertainties (Middle East, Ukraine), though no significant impact has been recorded to date.
- Stock Repurchases: The company repurchased 50,360 shares for $300,000 in Q1 2025 under an authorized program.
Investor Verification Checklist
- Customer Dependency: Verify the stability of the relationship with the single customer representing 69% of revenue and 87% of receivables.
- DOJ Investigation: Monitor updates on the Department of Justice investigation regarding Medicare billing codes and potential liability.
- Expense Trajectory: Assess whether the sharp increase in R&D (lobbying) and S&M expenses is a one-time event or a new baseline for operating costs.
- Cash Burn: Track the net cash used in operating activities ($2.7 million in Q1) against the $19.1 million cash balance to determine runway.
- Reimbursement Codes: Confirm the status of lobbying efforts for billing code reimbursement, which is a stated driver of R&D spend.